Global X China Biotech ETF (HKG:2820)

Assets	661.27M
Expense Ratio	0.68%
PE Ratio	27.54
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	-2.91%

Volume	10,600
Open	79.00
Previous Close	76.84
Day's Range	76.66 - 79.00
52-Week Low	56.70
52-Week High	84.50
Beta	0.47
Holdings	46
Inception Date	Jul 25, 2019

About 2820

The Global X China Biotech ETF strives to achieve investment returns that closely mirror the performance of its designated benchmark index, prior to the subtraction of any fees and expenses.

• Asset Class: Equity
• Category: Health Care
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2820
• Provider: Global X
• Index Tracked: Solactive China Biotech Index

Performance

2820 had a total return of -2.91% in the past year, including dividends. Since the fund's inception, the average annual return has been 4.25%.

Top 10 Holdings

85.51% of assets

Name	Symbol	Weight
Cash	n/a	24.62%
WuXi Biologics (Cayman) Inc.	2269	11.10%
BeOne Medicines AG	ONC	9.74%
Innovent Biologics, Inc.	1801	9.07%
WuXi AppTec Co., Ltd.	603259	8.76%
Akeso, Inc.	9926	5.78%
Sino Biopharmaceutical Limited	1177	4.46%
Jiangsu Hengrui Pharmaceuticals Co.,Ltd	600276	4.39%
Genscript Biotech Corporation	1548	3.85%
Hansoh Pharmaceutical Group Company Limited	3692	3.75%

Data Sources: S&P Global Market Intelligence, Financial Modeling Prep, and more

Historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Sep 23, 2026

Data Sources Report a data error